Prospective trial of intraoperative mitomycin C in the treatment of primary
pterygium.
Author(s): Cano-Parra J(1), Diaz-Llopis M, Maldonado MJ, Vila E, Menezo JL.
Affiliation(s): Author information:
(1)Department of Ophthalmology, La Fe University Hospital, Valencia, Spain.
Publication date & source: 1995, Br J Ophthalmol. , 79(5):439-41
AIMS: A prospective, randomised, double blind, placebo controlled study of
intraoperative mitomycin C as adjunctive treatment of primary pterygium was
conducted.
METHODS: A total of 66 eyes of 54 patients with primary pterygium were treated
with excision, with or without a single intraoperative application of mitomycin C
(0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this
adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months).
RESULTS: Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited
recurrences whereas only one of 30 eyes (3.33%) treated with excision and
intraoperative application of mitomycin C had recurrence (p = 0.0006). Neither
serious ocular complications nor systemic toxicity were noted in the mitomycin C
treated group.
CONCLUSION: Intraoperative mitomycin C appears to be an effective and safe
adjunctive treatment of primary pterygium.
|